Sawai Group Holdings Co., Ltd.
Sawai Group Holdings Co., Ltd.
- Market cap
- $1.33B
- P/E ratio
- 18.45
Your view on SWGHF
Overview
What the company does, where it operates, and who runs it.
About Sawai Group Holdings Co., Ltd.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Mitsuo Sawai
- Headquarters
- 5-2-30, Miyahara, Osaka, JP
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Mitsuo Sawai
- Headquarters
- 5-2-30, Miyahara, Osaka, JP
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States.
The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, granules, capsules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, chemotherapeutic agents, etc., as well as vitamin preparations.
It sells its generic drugs to distributors, wholesalers, and retailers in Japan and the United States. The company was founded in 1929 and is headquartered in Osaka, Japan.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Sawai Group Holdings Co., Ltd.. Starting points for Sawai Group Holdings Co., Ltd.: P/E 18.4, EPS $87.16, beta 0.04 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Sawai Group Holdings Co., Ltd.. Sawai Group Holdings Co., Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Sawai Group Holdings Co., Ltd.. Trailing twelve-month EPS for Sawai Group Holdings Co., Ltd. stands at $87.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Mar 2027 | Next yearYear to Mar 2028 |
|---|---|---|---|---|
| Average estimate | JPY 62.65 | JPY 15.15 | JPY 133.20 | JPY 152.95 |
| Lowest estimate | JPY 60.00 | JPY 14.51 | JPY 128.30 | JPY 147.33 |
| Highest estimate | JPY 65.57 | JPY 15.86 | JPY 138.65 | JPY 159.21 |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | JPY 0.271 | −JPY 0.021 | JPY 91.071 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Mar 2027 | Next yearYear to Mar 2028 |
|---|---|---|---|---|
| Average estimate | JPY 58.59B | JPY 50.18B | JPY 210.68B | JPY 222.06B |
| Lowest estimate | JPY 56.77B | JPY 48.48B | JPY 206.37B | JPY 214.13B |
| Highest estimate | JPY 59.75B | JPY 52.93B | JPY 215.74B | JPY 230.63B |
| Number of analysts | 4 | 4 | 9 | 9 |
| A year ago | JPY 56.07B | JPY 47.11B | JPY 202.95B | — |
| Growth vs a year ago | +4.5% | +6.5% | +3.8% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Sawai Group Holdings Co., Ltd.. Sawai Group Holdings Co., Ltd. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| HEMPHemp, Inc | Healthcare | OTC | $882,950 | ||
| HENCHero Technologies Inc. | Healthcare | OTC | $55,269 | ||
| HKMPFHikma Pharmaceuticals PLC | Healthcare | OTC | $4.8B | ||
| HKMPYHikma Pharmaceuticals PLC | Healthcare | OTC | $5.0B | ||
| HLBBFH. Lundbeck A/S | Healthcare | OTC | $4.9B | ||
| HLNHaleon plc | Healthcare | NYSE | $39.8B | ||
| HLNCFHaleon plc | Healthcare | OTC | $46.5B | ||
| HLS.TOHLS Therapeutics Inc. | Healthcare | TSX | $112.9M | ||
| HLTRFHLS Therapeutics Inc. | Healthcare | OTC | $105.1M | ||
| HLUBFH. Lundbeck A/S | Healthcare | OTC | $5.8B | ||
| HMDCFHutchison China Ltd. | Healthcare | OTC | $2.6B | ||
| HMPQHempAmericana, Inc | Healthcare | OTC | $291,753 | ||
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Sawai Group Holdings Co., Ltd.